Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04255680 · ClinicalTrials.gov registry record
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia
A clinical trial, sponsored by Larimar Therapeutics.
- Completed
- Registry status
- 20
- Enrollment target
NCT04255680: Completed study, sponsored by Larimar Therapeutics.
NCT04255680 is a clinical trial that has completed, run by Larimar Therapeutics. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04255680 has completed, sponsored by Larimar Therapeutics.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.
Primary Outcome
Difference in frataxin levels, specific RNAs and proteins between FRDA patients and control patients.
Interventions
- DIAGNOSTIC_TEST Buccal Swabs and Blood Draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2020-06-30 |
What the finished NCT04255680 record still lists
NCT04255680 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Buccal Swabs and Blood Draws is the first listed.
NCT04255680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04255680 about?
NCT04255680 is a clinical study titled "A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia". To test the variability of specific ribonucleic acid (RNA) and proteins as well as frataxin levels in samples of blood and buccal cells taken directly from patients with Friedreich's ataxia (FRDA) in order to confirm potential new biomarkers of disease in patients with FRDA.
What is the current status of trial NCT04255680?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2020-01-14. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04255680?
The interventions under investigation include: Buccal Swabs and Blood Draws (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04255680?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI